Searchable Patents Journal

Search details
          Search details help

   Results per page

Currently viewing: Intellectual Property Office - Patents Journal : SPCs
From 2016 October 26th - 6649 to 2016 October 26th - 6649
Refine: 

  • Help on this tab
    • Page
    • Previous
    • 1
    • Next
Publication
Date
SPC No.SPC
Category
Details
Rows may repeat to show multiple inventors or applicants depending on "Sort By"
26 October 2016
(Journal 6649)
SPC/GB16/012GrantedApplicant: Novartis Pharma AG
Lichtstrasse 35, 4056 Basel, Switzerland

Product: Valsartan and amlodipine and pharmaceutically acceptable salts thereof

Product Type: Medicinal
Authorised: CH CH;57771/001 22 December 2006
CH CH;57771/002 22 December 2006
CH CH;57771/003 22 December 2006
UK EU/1/06/371/001-024 16 January 2007
UK EU/1/06/372/001-024 16 January 2007

Authorised Extension:

Patent No: EP2322174
Title: Combined use of valsartan and calcium channel blockers for therapeutic purposes.

SPC No: SPC/GB16/012
Date Granted: 4 October 2016
Maximum Period Expires On: 21 December 2021
26 October 2016
(Journal 6649)
SPC/GB16/018GrantedApplicant: Sanofi Pasteur Limited
1755 Steeles Avenue, West Toronto, Ontario, M2R 3T4, Canada

Product: Diptheria, tetanus, pertussis pertussis toxoid, filamentous haemagglutinin, pertactin, Fimbriae Types 2 and 3), hepatitis B surface antigen (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)

Product Type: Medicinal
Authorised: UK EU/1/15/1079/001 17 February 2016
UK EU/1/15/1079/002 17 February 2016
UK EU/1/15/1079/003 17 February 2016
UK EU/1/15/1079/004 17 February 2016
UK EU/1/15/1079/005 17 February 2016
UK EU/1/15/1079/006 17 February 2016
UK EU/1/15/1079/007 17 February 2016

Authorised Extension:

Patent No: EP0826001
Title: Acellular pertussis vaccines and methods of preparation thereof

SPC No: SPC/GB16/018
Date Granted: 4 October 2016
Maximum Period Expires On: 1 May 2021
26 October 2016
(Journal 6649)
SPC/GB16/051LodgedApplicant: CSL Behring AG
Wankdorfstrasse 10, 3000 Bern 22, Switzerland

Product: Human normal immunoglobulin

Product Type: Medicinal
Authorised: UK EU/1/11/687/001-012 18 April 2011

Authorised Extension:

Patent No: EP2364730
Title: Immunoglobulin preparations having increased stability

SPC No: SPC/GB16/051
Date Lodged: 26 September 2016
  • Page 1 of 1 (3 hits)
  • Page
  • Previous
  • 1
  • Next

Tell us about a problem